Antimicrobial resistance: the good, the bad, and the ugly

Emerg Top Life Sci. 2020 Sep 8;4(2):129-136. doi: 10.1042/ETLS20190194.

Abstract

As the Royal Society for Biology (RSB) was forming 10 years ago, antimicrobial resistance (AMR) was being heralded as the next threat with a magnitude on a par with global warming. Just a few years later, in 2016, Jim O'Neill's report was published laying out recommendations for tackling drug-resistant infections globally. Where are we now, and what are the challenges ahead? As a slow burner, how will the impact of AMR compare against the recent rapid devastation of the COVID-19 pandemic, and how can we channel some of the good things that come from it (like the awareness and technique of effective hand hygiene) to help us combat AMR speedily and definitively?

Keywords: antibiotic; antimicrobial resistance; bacteria; biofilms.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacterial Infections / drug therapy*
  • Betacoronavirus / drug effects
  • Biofilms
  • COVID-19
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / prevention & control
  • Drug Resistance, Bacterial / drug effects*
  • Humans
  • Infection Control
  • Klebsiella pneumoniae / drug effects
  • Pandemics / prevention & control
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / prevention & control
  • Public Health
  • SARS-CoV-2

Substances

  • Anti-Bacterial Agents